Andrew Hollman Meyer - Jun 10, 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Chief Business Officer
Signature: /s/ Tighe Reardon, Attorney-in-Fact
Stock symbol: JANX
Transactions as of: Jun 10, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/10/2021, 07:15 PM
Next filing: Jan 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	JANX	Common Stock						59.4K	Jun 10, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	JANX	Stock Option (right to buy)							Jun 10, 2021	Common Stock	151K	$4.21	Direct	F1
holding	JANX	Stock Option (right to buy)							Jun 10, 2021	Common Stock	128K	$10.59	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/4th of the shares vest one year after March 10,2021 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2	1/4th of the shares vest one year after May 14, 2021 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.